Drug and medical device manufacturers have been reporting financial relationships with physicians to the U.S. government for years under the Physician Payments Sunshine Act.
Biopharma M&A has picked up this year with deals dominated by rare diseases and cancer, more than $34 billion all told, not counting Takeda's hefty $62 billion offer for Shire.
The J.P. Morgan Healthcare Conference is a yearly opportunity for the biopharma industry to make major announcements and let analysts, investors and the media pick the brains of top execs